
    
      Patients are randomized to receive topical therapy with placebo (vehicle alone) or HPMPC at
      either 0.3 or 1.0 percent once daily for 5 days. Patients are assessed to day 15; those with
      no significant toxicity are eligible to receive open-label topical HPMPC for up to 6 months.
    
  